Johnson & Johnson (NYSE:JNJ) Shares Sold by Provident Trust Co.

Provident Trust Co. decreased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 2.8% during the 3rd quarter, Holdings Channel reports. The firm owned 2,641 shares of the company’s stock after selling 75 shares during the quarter. Johnson & Johnson comprises about 0.0% of Provident Trust Co.’s holdings, making the stock its 21st biggest position. Provident Trust Co.’s holdings in Johnson & Johnson were worth $431,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. RKL Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.1% in the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after acquiring an additional 1,010 shares in the last quarter. Geller Advisors LLC lifted its position in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after acquiring an additional 648 shares in the last quarter. Simon Quick Advisors LLC lifted its position in shares of Johnson & Johnson by 296.9% in the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after acquiring an additional 6,537 shares in the last quarter. Lokken Investment Group LLC lifted its position in shares of Johnson & Johnson by 1.6% in the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after acquiring an additional 201 shares in the last quarter. Finally, Keebeck Alpha LP lifted its position in Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after buying an additional 525 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Activity

In other news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $168.74 on Monday. The stock’s 50-day moving average is $176.14 and its 200-day moving average is $171.20. The company has a market cap of $441.17 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 3.19 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Analysts Set New Price Targets

Several research firms recently weighed in on JNJ. SVB Leerink reduced their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Morgan Stanley reduced their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Barclays began coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Atlantic Securities reduced their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.